QuantumLeap Healthcare Collaborative
Standard Therapy(QuantumLeap Healthcare Collaborative)은 HER2 표적 ADC로, Breast Neoplasms; Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting chimeric antigen receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 9% (ClinicalTrials.gov NCT02357342). 차별점: novel docetaxel derivative JJH201601 in glioma: targeting ribosome biogenesis and enhancing temozolomide sensitivity.
HER2
Breast Neoplasms; Breast Cancer
Recruiting
CAR-T cell product quality and long-term functionality
lentiviral gene therapy
humanized antibody capable of recognizing both LILRB3 and LILRB4
novel docetaxel derivative JJH201601 in glioma: targeting ribosome biogenesis and enhancing temozolomide sensitivity
targeting chimeric antigen receptor
T cells indicated activation
apoptosis, EdU incorporation, and cell cycle distribution
biomarker of disease biology
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
QuantumLeap Healthcare Collaborative
Standard Therapy(QuantumLeap Healthcare Collaborative)은 HER2 표적 ADC로, Breast Neoplasms; Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting chimeric antigen receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 9% (ClinicalTrials.gov NCT02357342). 차별점: novel docetaxel derivative JJH201601 in glioma: targeting ribosome biogenesis and enhancing temozolomide sensitivity.
HER2
Breast Neoplasms; Breast Cancer
Recruiting
CAR-T cell product quality and long-term functionality
lentiviral gene therapy
humanized antibody capable of recognizing both LILRB3 and LILRB4
novel docetaxel derivative JJH201601 in glioma: targeting ribosome biogenesis and enhancing temozolomide sensitivity
targeting chimeric antigen receptor
T cells indicated activation
apoptosis, EdU incorporation, and cell cycle distribution
biomarker of disease biology
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.